FDA product code · Pathology

Neuramininase (Sialidase)

Name: FDA decisions, review times, recalls and adverse event reports for product code IBE
Creator: 510(k) Report

IBEClass I21 CFR 864.4400510(k) exempt0 decisions0 recalls

FDA lists IBE as exempt from 510(k): a device of this type needs no clearance unless one of the limits in 21 CFR 864.9 applies, such as a new intended use or a different fundamental technology. 0 FDA decisions. No recall names this code.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, pathology panel

Twenty years of IBE at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FIG. 1 — IBE by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in IBE? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Related product codes

Other codes under 21 CFR 864.4400.

IBD Hyaluronidase IBF Papain IBG Trypsin LIJ Peroxidase Anti-Peroxidase Immunohistochemical…IAZ Heparin IBC Diastase IBA Streptolysin O